• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

转移性非小细胞非鳞状肺癌患者的当前治疗算法

Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer.

作者信息

Melosky Barbara

机构信息

Medical Oncology, British Columbia Cancer Agency, Vancouver Centre , Vancouver, BC , Canada.

出版信息

Front Oncol. 2017 Mar 20;7:38. doi: 10.3389/fonc.2017.00038. eCollection 2017.

DOI:10.3389/fonc.2017.00038
PMID:28373963
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5357779/
Abstract

The treatment paradigm for metastatic non-small cell, non-squamous lung cancer is continuously evolving due to new treatment options and our increasing knowledge of molecular signal pathways. As a result of treatments becoming more efficacious and more personalized, survival for selected groups of non-small cell lung cancer (NSCLC) patients is increasing. In this paper, three algorithms will be presented for treating patients with metastatic non-squamous, NSCLC. These include treatment algorithms for NSCLC patients whose tumors have mutations, rearrangements, or wild-type/wild-type tumors. As the world of immunotherapy continues to evolve quickly, a future algorithm will also be presented.

摘要

由于新的治疗选择以及我们对分子信号通路的认识不断增加，转移性非小细胞非鳞状肺癌的治疗模式正在不断演变。随着治疗变得更加有效和个性化，部分非小细胞肺癌（NSCLC）患者的生存期正在延长。本文将介绍三种用于治疗转移性非鳞状NSCLC患者的算法。这些算法包括针对肿瘤有特定突变、重排或野生型/野生型肿瘤的NSCLC患者的治疗算法。随着免疫治疗领域的快速发展，还将介绍一种未来的算法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a023/5357779/f97766151a0e/fonc-07-00038-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a023/5357779/faa669431ff3/fonc-07-00038-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a023/5357779/f97766151a0e/fonc-07-00038-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a023/5357779/faa669431ff3/fonc-07-00038-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a023/5357779/f97766151a0e/fonc-07-00038-g002.jpg

相似文献

1
Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer.转移性非小细胞非鳞状肺癌患者的当前治疗算法
Front Oncol. 2017 Mar 20;7:38. doi: 10.3389/fonc.2017.00038. eCollection 2017.
2
Treatment algorithms for patients with metastatic non-small cell, non-squamous lung cancer.转移性非小细胞非鳞状肺癌患者的治疗方案。
Front Oncol. 2014 Sep 29;4:256. doi: 10.3389/fonc.2014.00256. eCollection 2014.
3
Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC.转移性非小细胞肺癌靶向治疗的最新进展
Front Oncol. 2016 May 4;6:112. doi: 10.3389/fonc.2016.00112. eCollection 2016.
4
The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer.血管生成抑制剂在免疫检查点抑制剂和靶向治疗时代的转移性非小细胞肺癌中的作用。
Curr Treat Options Oncol. 2019 Feb 18;20(3):21. doi: 10.1007/s11864-019-0617-6.
5
Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.免疫疗法单独或联合化疗作为非小细胞肺癌的一线治疗。
Curr Treat Options Oncol. 2020 Jul 27;21(8):69. doi: 10.1007/s11864-020-00768-2.
6
Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.表皮生长因子受体-酪氨酸激酶抑制剂在非小细胞肺癌中的更新。
J Chin Med Assoc. 2013 May;76(5):249-57. doi: 10.1016/j.jcma.2013.01.010. Epub 2013 Mar 22.
7
Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC.转移性非小细胞肺癌的潜在靶点及当前临床试验
Front Oncol. 2014 Nov 25;4:329. doi: 10.3389/fonc.2014.00329. eCollection 2014.
8
Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies.转移性鳞状细胞非小细胞肺癌（NSCLC）：免疫疗法打破药物治疗模式
Drugs Context. 2015 Oct 14;4:212289. doi: 10.7573/dic.212289. eCollection 2015.
9
Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.已知存在突变或重排的晚期非小细胞肺癌的管理：最新证据与治疗方法
Ther Adv Respir Dis. 2016 Apr;10(2):113-29. doi: 10.1177/1753465815617871. Epub 2015 Nov 30.
10
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.局部晚期和转移性非小细胞肺癌的系统治疗：综述。
JAMA. 2019 Aug 27;322(8):764-774. doi: 10.1001/jama.2019.11058.

引用本文的文献

1
Nitroglycerin-induced downregulation of AKT- and ERK1/2-mediated radiation-sensitive 52 expression to enhance pemetrexed-induced cytotoxicity in human lung cancer cells.硝酸甘油诱导AKT和ERK1/2介导的辐射敏感蛋白52表达下调，以增强培美曲塞对人肺癌细胞的细胞毒性。
Toxicol Res (Camb). 2022 Mar 26;11(2):299-310. doi: 10.1093/toxres/tfac013. eCollection 2022 Apr.
2
Real-World Utilization of Target- and Immunotherapies for Lung Cancer: A Scoping Review of Studies Based on Routinely Collected Electronic Healthcare Data.基于常规电子医疗保健数据的肺癌靶向和免疫治疗的真实世界应用：研究的范围综述。
Int J Environ Res Public Health. 2021 Jul 19;18(14):7679. doi: 10.3390/ijerph18147679.
3

本文引用的文献

1
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.阿法替尼与吉非替尼治疗表皮生长因子受体（EGFR）突变阳性的晚期非小细胞肺癌患者：IIb期LUX-Lung 7试验的总生存数据
Ann Oncol. 2017 Feb 1;28(2):270-277. doi: 10.1093/annonc/mdw611.
2
Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study).对于接受铂类化疗后未进展的晚期非小细胞肺癌患者，疾病进展时维持使用厄洛替尼与使用厄洛替尼的对比研究（IUNO研究）。
Lung Cancer. 2016 Dec;102:30-37. doi: 10.1016/j.lungcan.2016.10.007. Epub 2016 Oct 20.
3
Mechanisms for Modulating Anoikis Resistance in Cancer and the Relevance of Metabolic Reprogramming.
癌症中调节失巢凋亡抗性的机制及代谢重编程的相关性
Front Oncol. 2021 Mar 29;11:626577. doi: 10.3389/fonc.2021.626577. eCollection 2021.
4
The Deubiquitinase USP4 Stabilizes Twist1 Protein to Promote Lung Cancer Cell Stemness.去泛素化酶USP4稳定Twist1蛋白以促进肺癌细胞干性。
Cancers (Basel). 2020 Jun 15;12(6):1582. doi: 10.3390/cancers12061582.
5
Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients.采用独特分子标识符标记的超深度大规模平行测序与数字液滴 PCR 检测和定量肺癌患者循环肿瘤 DNA 的性能相当。
PLoS One. 2019 Dec 16;14(12):e0226193. doi: 10.1371/journal.pone.0226193. eCollection 2019.
6
The emerging treatment landscape of advanced non-small cell lung cancer.晚期非小细胞肺癌的新兴治疗格局
Ann Transl Med. 2018 Apr;6(8):138. doi: 10.21037/atm.2017.11.07.
7
A real-world study of treatment patterns and survival outcome in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer.晚期间变性淋巴瘤激酶阳性非小细胞肺癌治疗模式与生存结局的真实世界研究
Oncol Lett. 2018 Jun;15(6):8703-8710. doi: 10.3892/ol.2018.8444. Epub 2018 Apr 5.
8
In Vivo SELEX of an Inhibitory NSCLC-Specific RNA Aptamer from PEGylated RNA Library.从聚乙二醇化RNA文库中对抑制性非小细胞肺癌特异性RNA适配体进行体内SELEX筛选。
Mol Ther Nucleic Acids. 2018 Mar 2;10:187-198. doi: 10.1016/j.omtn.2017.12.003. Epub 2017 Dec 9.
9
Personalised medicine in sleep respiratory disorders: focus on obstructive sleep apnoea diagnosis and treatment.睡眠呼吸障碍的个体化医学：以阻塞性睡眠呼吸暂停的诊断和治疗为重点。
Eur Respir Rev. 2017 Oct 25;26(146). doi: 10.1183/16000617.0069-2017. Print 2017 Dec 31.
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
奥希替尼治疗预处理 EGFR Thr790Met 阳性的晚期非小细胞肺癌（AURA2）：一项多中心、开放标签、单臂、2 期研究。
Lancet Oncol. 2016 Dec;17(12):1643-1652. doi: 10.1016/S1470-2045(16)30508-3. Epub 2016 Oct 14.
4
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.帕博利珠单抗对比化疗用于 PD-L1 阳性非小细胞肺癌。
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
5
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.克唑替尼治疗后化疗和克唑替尼治疗的 ALK 重排非小细胞肺癌患者的塞瑞替尼全身和颅内活性的多中心 II 期研究：ASCEND-2 的结果。
J Clin Oncol. 2016 Aug 20;34(24):2866-73. doi: 10.1200/JCO.2015.65.5936. Epub 2016 Jul 18.
6
BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer.贝弗利：一项随机开放标签III期试验的原理与设计，该试验比较了贝伐单抗联合厄洛替尼与单纯厄洛替尼作为表皮生长因子受体（EGFR）突变的晚期非鳞状非小细胞肺癌患者一线治疗方案的疗效。
Clin Lung Cancer. 2016 Sep;17(5):461-465. doi: 10.1016/j.cllc.2016.04.001. Epub 2016 Apr 22.
7
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.帕博利珠单抗对比多西他赛用于治疗后 PD-L1 阳性的、晚期非小细胞肺癌（KEYNOTE-010）：一项随机对照试验。
Lancet. 2016 Apr 9;387(10027):1540-1550. doi: 10.1016/S0140-6736(15)01281-7. Epub 2015 Dec 19.
8
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.阿来替尼用于ALK阳性、克唑替尼耐药的非小细胞肺癌：一项单组、多中心、2期试验。
Lancet Oncol. 2016 Feb;17(2):234-242. doi: 10.1016/S1470-2045(15)00488-X. Epub 2015 Dec 19.
9
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.洛拉替尼的ALK耐药突变L1198F导致对克唑替尼重新致敏。
N Engl J Med. 2016 Jan 7;374(1):54-61. doi: 10.1056/NEJMoa1508887. Epub 2015 Dec 23.
10
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.克唑替尼治疗后进展的间变性淋巴瘤激酶阳性非小细胞肺癌患者中阿来替尼的疗效：一项全球 II 期研究。
J Clin Oncol. 2016 Mar 1;34(7):661-8. doi: 10.1200/jco.2015.63.9443. Epub 2015 Nov 23.